Charles Lawrence Loprinzi, MD

Professor

  • 23756 Citations
  • 78 h-Index
1982 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 9 Similar Profiles
Hot Flashes Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Placebos Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Peripheral Nervous System Diseases Medicine & Life Sciences
Megestrol Acetate Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1983 2015

Survivorship research established investigator award

Loprinzi, C. L.

National Institutes of Health

6/1/0812/31/13

Project: Research projectResearch Scientist Award

Survival Rate
Research Personnel
Mentors
Research
Organized Financing

CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY

Loprinzi, C. L.

National Institutes of Health

6/1/993/31/05

Project: Research projectResearch Project

Chemoprevention
Immunity
Skin Neoplasms
imiquimod
Infection

INHIBITION OF ORNITHINE DECARBOXYLASE BY ORAL COMPOUNDS

Loprinzi, C. L.

National Institutes of Health

1/1/856/30/85

Project: Research projectClinical Investigator Award (CIA)

Ornithine Decarboxylase
Skin
Tetradecanoylphorbol Acetate
Eflornithine
Retinoids

COMMUNITY CLINICAL ONCOLOGY PROGRAM

Loprinzi, C. L., Moertel, C. G., O'Connell, M., Moertel, C. G. & Moertel, C. G.

National Institutes of Health

9/15/835/31/15

Project: Research projectCooperative Clinical Research--Cooperative Agreements

Medical Oncology
Neoplasms
Research
Radiotherapy
Quality Control

Research Output 1982 2018

Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism

Simmons, B., Wysokinski, W., Saadiq, R. A., Bott-Kitslaar, D., Henkin, S., Casanegra, A., Lenz, C., Daniels, P., Bjarnason, H., Vargas, E., Hodge, D., Holton, S. J., Cerhan, J. R., Loprinzi, C. & McBane, R., Aug 1 2018, In : European Journal of Haematology. 101, 2, p. 136-142 7 p.

Research output: Contribution to journalArticle

Enoxaparin
Second Primary Neoplasms
Venous Thromboembolism
Safety
Low Molecular Weight Heparin

Nasal vestibulitis: an under-recognized and under-treated side effect of cancer treatment?

Cathcart-Rake, E., Smith, D., Zahrieh, D., Jatoi, A., Yang, P. & Loprinzi, C. L., May 24 2018, (Accepted/In press) In : Supportive Care in Cancer. p. 1-6 6 p.

Research output: Contribution to journalArticle

Nose
Taxoids
Neoplasms
Vascular Endothelial Growth Factor A
Therapeutics

Oxybutynin for hot flashes due to androgen deprivation in men

Smith, T. J., Loprinzi, C. L. & Deville, C., May 3 2018, In : New England Journal of Medicine. 378, 18, p. 1745-1746 2 p.

Research output: Contribution to journalLetter

Hot Flashes
Androgens
oxybutynin

Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline

Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., Nguyen, L. H., Seigel, C. & Baile, W. F., Feb 1 2018, In : Obstetrical and Gynecological Survey. 73, 2, p. 96-97 2 p.

Research output: Contribution to journalComment/debate

Consensus
Communication
Guidelines

Ten-year trends in antiemetic prescribing in patients receiving highly emetogenic chemotherapy

O’Sullivan, C. C., Van Houten, H. K., Sangaralingham, L. R., Leal, A. D., Shinde, S., Liu, H., Ettinger, D., Loprinzi, C. L. & Ruddy, K. J., Mar 1 2018, In : JNCCN Journal of the National Comprehensive Cancer Network. 16, 3, p. 294-299 6 p.

Research output: Contribution to journalArticle

Antiemetics
fosaprepitant
Drug Therapy
Neurokinin-1 Receptor Antagonists
Guidelines